Detalles de la búsqueda
1.
Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamide.
Am J Hematol
; 99(3): 350-359, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38165016
2.
Peripheral levels of monocytic myeloid-derived suppressive cells before and after first induction predict relapse and survivals in AML patients.
J Cell Mol Med
; 26(21): 5486-5492, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36226545
3.
Effectiveness of a third dose of BNT162b2 anti-SARS-CoV-2 mRNA vaccine over a 6-month follow-up period in allogenic hematopoietic stem cells recipients.
Hematol Oncol
; 40(5): 1097-1099, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-35468662
4.
Dramatic Recovery after Etoposide Phosphate Infusion for Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome following Treatment with Tisagenlecleucel in a Young Patient with Relapsed Acute Lymphoblastic Leukemia: A Case Report.
Acta Haematol
; 145(5): 537-541, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35724631
5.
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study.
Ann Hematol
; 98(6): 1441-1447, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-30874851
6.
Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study.
Ann Hematol
; 98(6): 1435-1440, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-30874850
7.
Interest of a third dose of BNT162b2 anti-SARS-CoV-2 messenger RNA vaccine after allotransplant.
Br J Haematol
; 196(5): e38-e40, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34671982
8.
Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy.
Br J Haematol
; 196(2): 360-362, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34476803
9.
Azacitidine in patients older than 80 years with acute myeloid leukaemia or myelodysplastic syndromes: a report on 115 patients.
Br J Haematol
; 190(3): 461-464, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32394477
10.
Late Relapse after Allogeneic Stem Cell Transplantation in Patients Treated for Acute Myeloid Leukemia: Relapse Incidence, Characteristics, Role of Conditioning Regimen, and Outcome.
Cancers (Basel)
; 16(7)2024 Apr 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38611097
11.
Successful treatment of congenital erythropoietic porphyria using matched unrelated hematopoietic stem cell transplantation in an adult: A case report.
Skin Health Dis
; 4(2): e342, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38577034
12.
Post-transplant cyclophosphamide as sole GHVD prophylaxis after matched reduced-intensity conditioning allotransplant.
Clin Transl Med
; 13(4): e1242, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37140099
13.
Assessment of monocytic-myeloid-derived suppressive cells (M-MDSC) before and after allogeneic hematopoietic stem cell transplantation in acute leukemia patients.
EJHaem
; 4(4): 1089-1095, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-38024608
14.
Non-Expressed Donor KIR3DL1 Alleles May Represent a Risk Factor for Relapse after T-Replete Haploidentical Hematopoietic Stem Cell Transplantation.
Cancers (Basel)
; 15(10)2023 May 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-37345091
15.
Tocilizumab in combination with a standard induction chemotherapy in acute myeloid leukaemia patients (TOCILAM study): a single-centre, single-arm, phase 1 trial.
EClinicalMedicine
; 64: 102254, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37786451
16.
Anti-SARS-CoV-2 vaccines in recipient and/or donor before allotransplant.
EJHaem
; 3(2): 484-487, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35313664
17.
SARS-CoV-2 T-Cell Responses in Allogeneic Hematopoietic Stem Cell Recipients following Two Doses of BNT162b2 mRNA Vaccine.
Vaccines (Basel)
; 10(3)2022 Mar 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35335079
18.
Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients.
Cells
; 11(19)2022 09 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-36230971
19.
B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.
Transplant Cell Ther
; 28(5): 279.e1-279.e4, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35218998
20.
Monoclonal antibodies as an addition to current myeloma therapy strategies.
Expert Rev Anticancer Ther
; 21(1): 33-43, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33052750